Protective efficacy of rebamipide for the aspirin induced gastric/small intestinal injury;the clinical trials for volunteers

Protective efficacy of rebamipide for the aspirin induced gastric/small intestinal injury;the clinical trials for volunteers - Protective efficacy of rebamipide for the aspirin induced gastric/small intestinal injury

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000013845

Enrollment

Registered

2014-04-30

Start date

2013-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

NSAIDs induced small intestinal injury

Interventions

LDA(100mg) and Omeprazole 10mg/day for 2 weeks by oral administration LDA(100mg) and Rebamipide 300mg/day for 2 weeks by oral administration LDA(100mg) and Rebamipide 900mg/day for 2 weeks by oral adm

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Healthy adults who are 20years or older,and less than 80years of age at the time of obtaining informed consent.

Exclusion criteria

Exclusion criteria: not accepted the above informed concent

Design outcomes

Primary

Measure	Time frame
Evaluation of the small intestinal injuries induced by NSAIDs	—

Secondary

Measure	Time frame
Safety	—

Countries

Japan

Contacts

Public ContactEiji Umegaki

Osaka Medical College Second Dep of Internal Medicine

in2038@poh.osaka-med.ac.jp072-683-1221

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026